Question Bank › Event-dense runway

Event-dense runway

Event-dense runway: management frames the coming quarters as a calendar of its own named, scheduled events

Calls Tested
422
Answered YES
22
Hit Rate
5.2%
rare by design

IMAX Corporation (IMAX) — this company's answers

NO on the Q2 2023 call 2023-07-26 B+
The model's full reasoning — Q2 2023 call → NO我们根据提供的财报电话会议记录,判断管理层是否将公司近期未来(未来几个季度)描述为一系列具体的、已命名的、已安排的公司特定事件,并将这些事件序列作为公司未来发展的核心。 分析管理层发言: - Rich Gelfond 提到“back half of the year as strong title as well, including film for IMAX releases June 2 and Aquaman and the Lost Kingdom, Apple's Napoleon from Ridley Scott and Killers of the Flower Mood from Martin Scorsese, both scheduled for exclusive theatrical release.” 这里提到了具体电影上映事件。 - 还提到“We now expect to program more than 40 local language films worldwide in '23, up from the 30 to 40 we initially projected.” 这是计划中的事件。 - 提到“we announced an agreement to sell worldwide rights to our forthcoming documentary, the Blue Angels to Amazon Studios” 这是具体事件。 - 提到“we recently took a significant strategic step with our proposal to acquire full ownership of our IMAX China subsidiary.” 这是战略步骤。 - 提到“we are exploring are there more of them that we could possibly refurbish and bring into service” 关于70毫米放映机,但这是探索性的。 - 提到“we are aggressively examining the possibility of how we can lever off this kind of amazing cultural event” 这是探索性的。 但管理层是否将未来几个季度组织为一系列具体事件?他们提到了电影上映、纪录片发行、收购中国子公司等,但这些都是分散的,并没有形成一个统一的“事件日历”作为核心叙事。他们更多是在讨论市场表现、品牌势头、签约和安装等。例如,他们强调“signings momentum”和“installations are ramping”,但这些是业务指标,不是具体事件。他们提到“we had 20 installations in the quarter”等,但这是回顾,不是未来计划。 关于未来,他们提到“we remain on track to deliver significant growth in system signings, installations, global box office and adjusted EBITDA for the full year.” 这是总体目标,不是具体事件序列。 他们提到“Q3 is off to an incredible box office start with our biggest July opening weekend ever” 这是回顾,不是未来计划。 他们提到“we are seeing exhibitors bring more IMAX to their existing multiplexes globally” 这是趋势。 他们提到“we are exploring”和“we are aggressively examining”等,表明是探索性的。 因此,管理层并没有将未来几个季度描述为一系列具体的、已命名的、已安排的公司特定事件,而是更多讨论市场趋势、品牌实力和业务增长。虽然有具体电影上映,但那是行业常规,不是公司自身的独特事件。而且他们也没有将事件序列作为核心叙事。 所以答案应为NO。

← Back to the full IMAX analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management frame the company's NEAR FUTURE — roughly the next few quarters — as a CALENDAR OF ITS OWN SPECIFIC, NAMED, ALREADY-SCHEDULED EVENTS, and treat working through that event sequence as the central story of where the company is heading? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent posture: the forward-looking discussion is organized around MULTIPLE distinct, concrete happenings that belong to the company itself and are expected to occur soon — each one identifiable and time-anchored in management's telling (this quarter, next quarter, by mid-year, this season, in the coming months). The events may take whatever form fits the industry — for example: a facility, line, site, store format, or capacity starting up or opening; a product, program, service, or offering launching or shipping; a ramp, rollout, or expansion beginning or reaching its next stage; a first delivery, first production, first cohort, or go-live; a submission, decision, certification, data readout, or approval date; a contract, program, or partnership commencing; a new market or channel switching on. What matters is that (a) there are SEVERAL such distinct company-specific events, not just one; (b) management anchors them in the near term with at least rough timing, presenting them as scheduled or in motion rather than aspirational; and (c) management treats this sequence of upcoming events — rather than general market conditions, demand trends, or cost management — as the main engine of the company's next stage, with the call's forward energy devoted to what is about to happen and how the company is preparing for each step. Answer NO if the forward discussion is chiefly about market conditions, demand strength or weakness, macro factors, pricing, or cost control, with no calendar of company-specific events. NO if there is only ONE meaningful upcoming event, however large. NO if the future items are vague ambitions, pipeline hopes, exploratory initiatives, or opportunities without stated near-term timing. NO if the named events are routine recurring housekeeping this business always has (ordinary seasonal openings at the usual pace, standard annual product refreshes, scheduled maintenance) that management does not present as changing the company's trajectory. NO if management mentions upcoming milestones only in passing while the call's substance is defending current results. NO if the events are mainly things happening TO the company from outside (market recoveries, customer budget cycles, industry conditions) rather than the company's own scheduled actions. NO if the event calendar appears only in an analyst's question or summary that management does not itself adopt. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
RCEL AVITA Medical, Inc. Q1 2024 2024-05-14 F
ERO Ero Copper Corp. Q1 2024 2024-05-10 A
LILA Liberty Latin America Ltd. Q4 2023 2024-02-23 C
BRBR BellRing Brands, Inc. Q4 2023 2023-11-21 B+
SBS Companhia de Saneamento Básico do Estado Q3 2023 2023-11-10 C+
PTN Palatin Technologies, Inc. Q4 2023 2023-09-29 D
NBTX Nanobiotix S.A. Q2 2023 2023-09-27 D
PTLO Portillo's Inc. Q2 2023 2023-08-05 B
BEAT BioTelemetry's Q4 2022 2023-03-17 D
ARWR Arrowhead Pharmaceuticals, Inc. Q4 2022 2022-11-28 D
FLL Full House Resorts, Inc. Q3 2022 2022-11-07 B
ASTS AST SpaceMobile, Inc. Q2 2022 2022-08-15 D
HROW Harrow Health, Inc. Q4 2021 2022-03-10 C
EEX Emerald Holding, Inc. Q2 2021 2021-08-01 C+
AGIO Agios Pharmaceuticals, Inc. Q3 2018 2018-11-01 C
ALKS Alkermes plc Q3 2018 2018-10-23 C
AU AngloGold Ashanti's Q2 2018 2018-08-20 B
ITCI Intra-Cellular Therapies, Inc. Q4 2017 2018-03-01 D
PCRX Pacira BioSciences, Inc. Q4 2017 2018-02-28 C
IONS Ionis Pharmaceuticals, Inc. Q1 2017 2017-05-09 C
FATE Fate Therapeutics, Inc. Q3 2016 2016-11-07 C
DUK Duke Energy Corporation Q2 2016 2016-08-04 B

How the model reasoned

PCRX · Q4 2017 → YESThe question is: Does management frame the company's NEAR FUTURE — roughly the next few quarters — as a CALENDAR OF ITS OWN SPECIFIC, NAMED, ALREADY-SCHEDULED EVENTS, and treat working through that ev...YES Management frames the near-term outlook (2018) as a concrete calendar of its own named, time-anchored events—nerve-block label expansion, C-section study readout, additional Phase 4 study launches, CMS reimbursement decisions, and new partnerships—treating the execution of this sequence as the primary driver of 2018 growth and strategic progress. These are presented as scheduled company actions rather than general market trends, with explicit timing (e.g., mid-year FDA meetings, second-half manufacturing ramp, AAOS programs) and positioned as the central story of where the company is heading.
AU · Q2 2018 → YESThe question is: Does management frame the company's NEAR FUTURE — roughly the next few quarters — as a CALENDAR OF ITS OWN SPECIFIC, NAMED, ALREADY-SCHEDULED EVENTS, and treat working through that ev...YES Management structures the forward outlook around a clear sequence of its own named, time-anchored events—Kibali underground ramp-up and Azambi hydropower station (Q3), Siguiri CIL circuit and power plants (Q4), Obuasi redevelopment milestones (first gold end-2019), Mponeng 6-month backfill plant start (H2), South Africa Section 189 process and wage negotiations (Q3), plus production upticks at multiple sites—presenting these as the primary drivers of the next stage rather than generic market or cost themes.
HROW · Q4 2021 → YESThe question is: Does management frame the company's NEAR FUTURE — roughly the next few quarters — as a CALENDAR OF ITS OWN SPECIFIC, NAMED, ALREADY-SCHEDULED EVENTS, and treat working through that ev...YES The transcript shows management organizing the near-term outlook around a clear sequence of its own named, time-anchored events: AMP-100 PDUFA on October 16 (with launch a few months later), Surface Opthalmics data readout in a few months, Melt Pharmaceuticals top-line data soon after, and internal product 18-month launches, plus MAQ-100 FDA meeting mid-year and relaunch preparations for IOPIDINE/MAXITROL/MOXEZA.

More from the question bank

Second engine igniting off the firstManagement is buying/committing capital at aThe leak is fixed: the company is keeping whDemand pull is outrunning the plan for one sBet-the-company financing already spent on hSaid-then-did: management reports back on itAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.